[1]Jeng WJ ,Papatheodoridis GV ,Lok ASF . Hepatitis B[J]. Lancet, 2023,401(10381):1039-1052. DOI: 10.1016/S0140-6736(22)01468-4 .
[2]Yan R ,Sun M ,Yang H ,et al. 2024 latest report on hepatitis B virus epidemiology in China: current status, changing trajectory, and challenges[J]. Hepatobiliary Surg Nutr, 2025,14(1):66-77. DOI: 10.21037/hbsn-2024-754 .
[3]专家共识编写组. 中国慢性乙型肝炎功能性(临床)治愈临床实践专家共识[J]. 中华肝脏病杂志, 2025,33(10):977-987. DOI: 10.3760/cma.j.cn501113-20250723-00286 .
[4]Xie C ,Lin BL ,Gao ZL ,et al. Peginterferon alpha-2b enhances HBsAg loss in nucleos(t)ide analogue-treated patients: findings from a large real-world study (Everest project)[J]. Hepatol Int, 2025,19(Suppl 1):S350-S351. DOI: 10.1007/s12072-025-10854-y .
[5]Allweiss L ,Testoni B ,Yu M ,et al. Quantification of the hepatitis B virus cccDNA: evidence based guidelines for monitoring the key obstacle of HBV cure[J]. Gut, 2023,72(5):972-983. DOI: 10.1136/gutjnl-2022-328380 .
[6]Bosch M ,Kallin N ,Donakonda S ,et al. A liver immune rheostat regulates CD8 T cell immunity in chronic HBV infection[J]. Nature, 2024,631(8022):867-875. DOI: 10.1038/s41586-024-07630-7 .
[7]Lampertico P ,Bogomolov PO ,Chulanov V ,et al. Phase 2 randomised study of bulevirtide as monotherapy or combined with Peg-IFNα-2a as treatment for chronic hepatitis delta[J]. Liver Int, 2025,45(2):e70008. DOI: 10.1111/liv.70008 .
[8]Asselah T ,Chulanov V ,Lampertico P ,et al. Bulevirtide combined with Pegylated interferon for chronic hepatitis D[J]. N Engl J Med, 2024,391(2):133-143. DOI: 10.1056/NEJMoa2314134 .
[9]Fu JL ,Mao Q ,Jin QL ,et al. Entry inhibitor hepalatide combined with pegylated interferonalpha 2a therapy resulted in cccDNA clearance in CHB patients: a phase II randomised, double-blind, placebo-controlled trial[J]. J Hepatol, 2025,82(Suppl 1):S52-S53.
[10]Liang X ,Fu X ,Guan Y ,et al. LBP-013 A phase Ib multiple dose ascending study of HH-006 in treatmentnaïve participants with chronic hepatitis B virus infection[J]. J Hepatol, 2026,84(Suppl 1):S73-S74. DOI: 10.1016/S0168-8278(26)00428-9 .
[11]Mak LY ,Hui RW ,Seto WK ,et al. Novel drug development in chronic hepatitis B infection: capsid assembly modulators and nucleic acid polymers[J]. Clin Liver Dis, 2023,27(4):877-893. DOI: 10.1016/j.cld.2023.05.004 .
[12]Yuen MF ,Agarwal K ,Jucov A ,et al. ALG-000184 (pevifoscorvir sodium) monotherapy in participants with chronic HBV infection: a phase 1, multicentre, randomised, dose escalation trial[J]. Lancet Gastroenterol Hepatol, 2026,11(3):218-231. DOI: 10.1016/S2468-1253(25)00293-6 .
[13]Yuen MF ,Agarwal K ,Jucov A ,et al. Oral once-daily 300 mg ALG-000184, a novel capsid assembly modulator, demonstrated profound and sustained suppression of HBV DNA to < 10 IU/mL in all treatment-naïve (TN) or currently-not-treated (CNT) subjects with chronic HBV Infection [J]. Hepatology, 2025,82(Suppl 1):S186-S187. DOI: 10.1097/HEP.0000000000001493 .
[14]Wang C ,Chen S ,Zhang Y ,et al. Safety and efficacy of GST-HG141, a novel HBV capsid assembly modulator, for the treatment of chronic hepatitis B patients with low-level viremia: a randomized, double-blind, placebo-controlled, multicenter phase II study[J]. EClinical Medicine, 2025,87:103400. DOI: 10.1016/j.eclinm.2025.103400 .
[15]Hou J ,Lim SG ,Buti M ,et al. Phase 3 Results of bepirovirsen treatment for chronic hepatitis B virus infection[J]. N Engl J Med, 2026,394(24):2395-2406. DOI: 10.1056/NEJMoa2515131 .
[16]Buti M ,Heo J ,Tanaka Y ,et al. Sequential Peg-IFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis B[J]. J Hepatol, 2025,82(2):222-234. DOI: 10.1016/j.jhep.2024.08.010 .
[17]Joshi S ,Freudenberg JM ,et al. Immunomodulation by bepirovirsen may induce killing of infected hepatocytes (B-Together study)[J]. Hepatol Int, 2026,20(1):46-58. DOI: 10.1007/s12072-025-10917-0 .
[18]左书凝,钟钰婷,赵建中. 乙型肝炎功能性治愈新药临床价值评价标准的探讨[J]. 临床肝胆病杂志, 2026,42(8):1773-1777. DOI: 10.12449/JCH260806 .
[19]Qiu Y ,Gao H ,Zhang D ,et al. LBP-031 AHB-137 monotherapy elicits high functional cure rates and sustained DNA suppression in treatment-naïve chronic hepatitis B participants: results from an ongoing phase II study[J]. J Hepatol, 2026,84(Suppl 1):S81. DOI: 10.1016/S0168-8278(26)00446-0 .
[20]Hou J ,Zhang W ,Xie Q ,et al. Xalnesiran with or without an Immunomodulator in Chronic Hepatitis B[J]. N Engl J Med, 2024,391(22):2098-2109. DOI: 10.1056/NEJMoa2405485 .
[21]Yuen MF ,Lim YS ,Yoon KT ,et al. VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study[J]. Lancet Gastroenterol Hepatol, 2024,9(12):1121-1132. DOI: 10.1016/S2468-1253(24)00237-1 .
[22]Wong GL ,Yuen MF ,Lin B ,et al. Elebsiran and PEG-IFNα for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial[J]. Nat Med, 2026,32(1):151-159. DOI: 10.1038/s41591-025-04049-z .
[23]Gane E ,Janczewska E ,Takehara T ,et al. Peginterferon-alpha-2a add-on to treatment with siRNA JNJ-73763989 in virologically suppressed chronic hepatitis B: The phase II PENGUIN study[J]. JHEP Rep, 2025,7(10):101516. DOI: 10.1016/j.jhepr.2025.101516 .
[24]Kennedy PTF ,Fung S ,Buti M ,et al. Peginterferon alpha-2a add-on to siRNA JNJ-73763989 in untreated patients with HBeAg-positive chronic hepatitis B virus (HBV) infection: the phase 2 REEF-IT study[J]. Gut, 2026,75(5):1043-1054. DOI: 10.1136/gutjnl-2025-336592 .
[25]Zhang Z ,Ma Y ,He Y ,et al. Inhibition of hepatitis B virus replication by a novel GalNAc-siRNA in vivo and in vitro[J]. ACS Omega, 2025,10(1):484-497. DOI: 10.1021/acsomega.4c06840 .
[26]Ling XE ,Chen L ,Lin JM ,et al. Combination therapy with HT101 and HT102 achieves rapid and progressive HBsAg loss in HBeAg-negative, Nucleos(T)ide analogues-suppressed patients: 12-week interim results from an ongoing multicenter, open-label phase Ib/IIa study[J]. Hepatology, 2026,83(1):E37-E38. DOI: 10.1097/HEP.0000000000001589 .
[27]Liang X ,Liang C ,Lin J , et al . LBP-012 High rate and sustained HBsAg loss achieved with HT101 plus HT102 combination therapy in HBeAg-negative, nucleos(t)ide analogue-suppressed patients: ongoing off-treatment results from a multicenter Ib/IIa study[J]. J Hepatol, 2026,84(S1):S73. DOI: 10.1016/S0168-8278(26)00427-7 .
[28]Yuen MF ,Gane E ,Holmes JA ,et al. The small interfering RNA imdusiran as single and multiple doses in healthy, randomised individuals and non-randomised individuals with chronic hepatitis B (AB-729-001): a phase Ia/b trial[J]. Lancet Gastroenterol Hepatol, 2026,11(7):579-601. DOI: 10.1016/S2468-1253(26)00058-0 .
[29]Yuen MF ,Heo J ,Nahass RG ,et al. Imdusiran (AB-729) administered every 8 weeks in combination with 24 weeks of pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects at end of IFN treatment[J]. J Hepatol, 2024,80(Suppl 1):S809-S901. DOI: 10.1016/S0168-8278(24)02236-0
[30]Gane EJ ,Aliuc J ,Conglan K ,et al. LBO-003 Tune-401: a first-in-class epigenetic silencer of HBV demonstrates deep and durable antiviral activity in the phase 1b/2a proof of concept Tune-401-001 study[J]. J Hepatol, 2026,84(S1):S8-S9. DOI: 10.1016/S0168-8278(26)00307-7 .
[31]Wong GL ,Lim S ,Agarwal K ,et al. Results from a phase 2a, open-label study to evaluate the safety and efficacy of novel combination therapies containing VIR-2218, selgantolimod, and nivolumab for the treatment of chronic hepatis B[J]. Hepatology, 2024,80(Suppl 1):S305. DOI: 10.1097/HEP.0000000000001077
[32]Asselah T ,Fung SK ,Akhan S ,et al. A phase 2 open-label study to evaluate safety, tolerability, efficacy, and pharmacodynamics of JNJ-73763989, nucleos(t)ide analogs, and a low-dose PD-1 inhibitor in patients with chronic hepatitis B: interim results of the OCTOPUS-1 study[J]. J Hepatol, 2024,80(S1):S27-S28. DOI: 10.1016/S0168-8278(24)00474-4 .
[33]Li Y ,Liu C ,Yang L ,et al. Add-on PD-1 inhibitor with Peg-IFNα therapy favors functional cure of chronic hepatitis B patients[J]. J Transl Int Med, 2026,14(1):123-133. DOI: 10.1515/jtim-2026-0018 .
[34]Zhu Q ,Gao ZL ,Yan LB ,et al. BRII-179 Induced functional immune response, demonstrating potential to improve chronic hepatitis B functional cure[J]. J Hepatol, 2024,80(S1):S87. DOI: 10.1016/S0168-8278(24)00474-4 .
[35]Yuen MF ,Lim YS ,Yoon KT ,et al. VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study[J]. Lancet Gastroenterol Hepatol, 2024,9(12):1121-1132. DOI: 10.1016/S2468-1253(24)00237-1 .
[36]Wong GL ,Yuen MF ,Kennedy P ,et al. Off-treatment antiviral efficacy and safety of repeat dosing of imdusiran followed by VTP-300 with or without nivolumab in virally-suppressed, non-cirrhotic subjects with chronic hepatitis B[J]. J Hepatol, 2025,82(S1):S79-S80. DOI: 10.1016/S0168-8278(25)00439-8 .
[37]AlMahtab M ,Akbar SMF ,Aguilar JC ,et al. Safety profile, antiviral capacity, and liver protection of a nasal therapeutic vaccine in patients with chronic hepatitis B: Five-year-follow-up outcomes after the end of treatment [J]. Front Med (Lausanne), 2023,10:1032531. DOI: 10.3389/fmed.2023.1032531 .
[38]Wei L ,Zhao T ,Zhang J ,et al. Efficacy and safety of a nanoparticle therapeutic vaccine in patients with chronic hepatitis B: a randomized clinical trial[J]. Hepatology, 2022,75(1):182-195. DOI: 10.1002/hep.32109 .
[39]Khanam A ,Chua JV ,Kottilil S . Immunopathology of chronic hepatitis B infection: role of innate and adaptive immune response in disease progression[J]. Int J Mol Sci, 2021,22(11):5497. DOI: 10.3390/ijms22115497 .
[40]Zheng P ,Dou Y ,Wang Q . Immune response and treatment targets of chronic hepatitis B virus infection: innate and adaptive immunity[J]. Front Cell Infect Microbiol, 2023,13:1206720. DOI: 10.3389/fcimb.2023.1206720 .
[41]王福生,张政. 慢性乙型肝炎病毒感染的免疫发病机制研究进展[J]. 中华肝脏病杂志, 2021,29(6):481-485. DOI: 10.3760/cma.j.cn501113-20210308-00110 .
[42]Ye B ,Liu X ,Li X ,et al. T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance[J]. Cell Death Dis, 2015,6:e1694. DOI: 10.1038/cddis.2015.42 .
[43]Lau G ,Marcellin P ,Peters MG ,et al. New perspectives in the development of immunomodulatory therapies for chronic hepatitis B[J]. J Hepatol, 2023,78(6):1235-1248.
[44]Liu Y ,Li H ,Zhang Z ,et al. Advances in novel therapeutic strategies for chronic hepatitis B: from viral suppression to functional cure[J]. J Hepatol, 2023,79(5):1285-1300. DOI: 10.1016/j.jhep.2023.06.012 .
[45]Moucari R ,Korevaar A ,Lemoine M ,et al. Immune checkpoint inhibitors and chronic viral hepatitis: mechanisms, safety and future perspectives[J]. J Hepatol, 2022,77(5):1348-1360. DOI: 10.1016/j.jhep.2022.06.018 .
[46]Bertoletti A ,Ferrari C . Adaptive immunity in HBV infection[J]. J Hepatol, 2016,65(4):S71-S75. DOI: 10.1016/j.jhep.2016.04.026 .